Last reviewed · How we verify
DFDBA with atorvastatin
DFDBA with atorvastatin is a Bone graft material with adjunctive pharmaceutical agent Small molecule drug developed by Kamineni Institute of Dental Sciences. It is currently FDA-approved for Periodontal bone defects and regeneration, Alveolar bone loss associated with periodontitis, Dental implant site augmentation. Also known as: atorvastatin gel.
DFDBA (demineralized freeze-dried bone allograft) combined with atorvastatin promotes bone regeneration and reduces inflammation in periodontal and dental defects.
DFDBA (demineralized freeze-dried bone allograft) combined with atorvastatin promotes bone regeneration and reduces inflammation in periodontal and dental defects. Used for Periodontal bone defects and regeneration, Alveolar bone loss associated with periodontitis, Dental implant site augmentation.
At a glance
| Generic name | DFDBA with atorvastatin |
|---|---|
| Also known as | atorvastatin gel |
| Sponsor | Kamineni Institute of Dental Sciences |
| Drug class | Bone graft material with adjunctive pharmaceutical agent |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Periodontics / Oral Surgery |
| Phase | FDA-approved |
Mechanism of action
DFDBA is an allograft material that provides a scaffold for bone formation and contains osteoinductive proteins that stimulate new bone growth. Atorvastatin, a statin, enhances osteoblast differentiation and bone formation while reducing inflammatory markers, synergistically improving bone regeneration outcomes in dental applications.
Approved indications
- Periodontal bone defects and regeneration
- Alveolar bone loss associated with periodontitis
- Dental implant site augmentation
Common side effects
- Infection at graft site
- Graft rejection or resorption
- Swelling or edema
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFDBA with atorvastatin CI brief — competitive landscape report
- DFDBA with atorvastatin updates RSS · CI watch RSS
- Kamineni Institute of Dental Sciences portfolio CI
Frequently asked questions about DFDBA with atorvastatin
What is DFDBA with atorvastatin?
How does DFDBA with atorvastatin work?
What is DFDBA with atorvastatin used for?
Who makes DFDBA with atorvastatin?
Is DFDBA with atorvastatin also known as anything else?
What drug class is DFDBA with atorvastatin in?
What development phase is DFDBA with atorvastatin in?
What are the side effects of DFDBA with atorvastatin?
Related
- Drug class: All Bone graft material with adjunctive pharmaceutical agent drugs
- Manufacturer: Kamineni Institute of Dental Sciences — full pipeline
- Therapeutic area: All drugs in Dentistry / Periodontics / Oral Surgery
- Indication: Drugs for Periodontal bone defects and regeneration
- Indication: Drugs for Alveolar bone loss associated with periodontitis
- Indication: Drugs for Dental implant site augmentation
- Also known as: atorvastatin gel
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing